NCT03971123 is a Phase 1 clinical trial of Tricaprilin in Alzheimer Disease, sponsored by Cerecin.

Who is sponsoring NCT03971123?

NCT03971123 is sponsored by Cerecin.

What drugs are being tested in NCT03971123?

Interventions in NCT03971123: Tricaprilin, Tricaprilin, Placebo, Tricaprilin.

What condition does NCT03971123 study?

NCT03971123 studies Alzheimer Disease.

Is NCT03971123 still recruiting?

NCT03971123 is currently completed. Last updated 8 July 2020.

Last reviewed 2020-07-08 · How we verify

NCT03971123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Completed Phase 1 Last updated 8 July 2020

What this trial tests

Phase 1 trial testing Tricaprilin in Alzheimer Disease in 32 participants. Completed in 26 May 2020.

Timeline

30 August 2019

Primary endpoint
2 April 2020

26 May 2020

Quick facts

Lead sponsor	Cerecin
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	32
Start date	30 August 2019
Primary completion	2 April 2020
Estimated completion	26 May 2020
Sites	1 location across Australia

Drugs / interventions tested

Tricaprilin — full drug profile →
Tricaprilin — full drug profile →
Placebo
Tricaprilin — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Cerecin — full company profile →

Who can join

Adults 18 to 50, male only, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1, Single-center, Open-label Study, Healthy Adult Male Subjects. Part 1:Single-dose, Placebo-controlled, 3-Way Crossover PK Study Part 2: Single dose 2-way comparator PK Study

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050
Abstract: Posters: 13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020.
· 2020 · cited 2× · PMID 33169785 · DOI 10.14283/jpad.2020.58

Verify or expand the search:

Other trials of Tricaprilin

Trials testing the same drug.

NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed
NCT04268953 — Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production · Phase 1 · completed
NCT03628352 — Taste-masking Study for Tricaprilin in Sensory Panelists · Phase 1 · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Cerecin trials

Trials by the same sponsor.

NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
NCT05408780 — A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation · Phase 1 · completed
NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT05028114 — Tricaprilin Liquid Formulation PK Study · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03971123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerecin
Last refreshed: 8 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03971123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing